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Dublin, IrelandA B S T R A C TBackground: Utility values are required for economic evaluation
using cost-utility analyses. Often, generic measures such as the
EuroQol ﬁve-dimensional questionnaire are used, but this may not
appropriately reﬂect the health-related quality of life of patients with
cancer including myeloﬁbrosis. Objective: To derive a condition-
speciﬁc preference-based measure for myeloﬁbrosis using appropriate
existing measures, the Myeloﬁbrosis-Symptom Assessment Form and
the European Organisation for Research and Treatment of Cancer
Quality of Life 30 Questionnaire. Methods: Data from the Controlled
Myeloﬁbrosis Study with Oral JAK Inhibitor Treatment trial (n ¼ 309)
were used to derive the health state classiﬁcation system. Psycho-
metric and factor analyses were used to determine the dimensions of
the classiﬁcation system. Psychometric and Rasch analyses were then
used to select an item to represent each dimension. Item selection
was validated with experts. A selection of health states was valued
by members of the general population using time trade-off.
Finally, health state values were modeled using regression analysis
to produce utility values for every state. Results: The Myeloﬁbrosisee front matter & 2015 Published by Elsevier Inc.
(ISPOR).
.1016/j.jval.2015.07.004
ia@shefﬁeld.ac.uk.
ndence to: Clara Mukuria, Health Economics and D
Court, 30 Regent Street, Shefﬁeld S1 4DA, UK.8 dimensions has eight dimensions: physical functioning, emotional
functioning, fatigue, itchiness, pain under ribs on the left side,
abdominal discomfort, bone or muscle pain, and night sweats.
Regression models were estimated using time trade-off data from
246 members of the general population valuing a total of 33 states.
The best performing model was a random effects maximum like-
lihood model producing utility values ranging from 0.089 to 1.
Conclusions: The Myeloﬁbrosis 8 dimensions is a condition-speciﬁc
preference-based measure for myeloﬁbrosis. This measure can be
used to generate utility values for myeloﬁbrosis for any data set
containing the Myeloﬁbrosis-Symptom Assessment Form and the
European Organisation for Research and Treatment of Cancer Quality
of Life 30 Questionnaire data.
Keywords: EORTC QLQ-C30, MF-SAF, myeloﬁbrosis, preference-based
measure.
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Pharmacoeconomics and Outcomes Research (ISPOR).Introduction
Preference-based measures of health are used in cost-utility
analysis to inform health policy, such as by agencies like the
National Institute for Health and Care Excellence in England [1].
They are used to generate utility values for health-related quality
of life (HRQOL), which are combined with length of life to
generate a quality-adjusted life-year. The current National Insti-
tute for Health and Care Excellence reference case [1] prefers
utility values from the EuroQol ﬁve-dimensional questionnaire
(EQ-5D) [2]. The EQ-5D, however, may not be appropriate for all
patient groups or all populations [3,4].
Myeloﬁbrosis (MF) is a cancer characterized by scarring of the
bone marrow, progressive anemia, and enlarged spleen. Symp-
toms include consequences of enlarged spleen (pain or fullness
below the ribs on the left side, feeling full sooner than normal
when eating) and constitutional symptoms such as fatigue,
itching, weight loss, dyspnea, fever, and night sweats [5]. TheEQ-5D has been used in some cancer populations in which it has
been shown to be valid [4]. It has been argued, however, that the
EQ-5D does not appropriately reﬂect the HRQOL of all patients
with cancer [6].
A condition-speciﬁc measure has been successfully used in
the MF population, the Myeloﬁbrosis-Symptom Assessment Form
version 2.0 (MF-SAF 2.0). The MF-SAF 2.0 is based on the MF-SAF
[5,7], with seven items focusing on speciﬁc MF symptoms:
abdominal discomfort, pain under left ribs, early satiety, night
sweats, itching, bone or muscle pain, and inactivity. It was
developed to assess the speciﬁc symptoms of MF and other
myeloproliferative neoplasm conditions such as polycythemia
vera or essential thrombocythemia. The more generic cancer
measure the European Organisation for Research and Treatment
of Cancer Quality of Life 30 Questionnaire (EORTC QLQ-C30) has
also been used in this population. The EORTC QLQ-C30 is one of
the most commonly used generic cancer measures [8] consisting
of 30 questions across six functioning scales (physical, role,on behalf of International Society for Pharmacoeconomics and
ecision Science, School of Health and Related Research, University
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 8 4 6 – 8 5 5 847cognitive, emotional, social, and global quality of life) and nine
symptom scales (fatigue, nausea and vomiting, pain, dyspnea,
sleep disturbance, appetite loss, constipation, diarrhea, and
ﬁnancial impact). Although the EORTC QLQ-C30 has been
designed to be applicable for assessing generic aspects of quality
of life, it has limitations and a modular approach has been taken
in which cancer-speciﬁc modules are added to the core EORTC
QLQ-C30 [9]. Assessment of the psychometric performance of the
QLQ-C30 against MF measures indicate that the QLQ-C30 cap-
tures functioning and some generic symptom problems [10,11].
However, it does not cover MF-speciﬁc symptoms, which may be
important in this population, such as weight loss, itching, and
night sweats, nor is it as responsive as the MF-SAF 2.0 over time
[12]. There was also evidence that dimensions such as constipa-
tion and diarrhea were less relevant for MF populations [12]. A
number of validated EORTC QLQ-C30 add-on cancer-speciﬁc
modules exist, but there is none for MF.
A further limitation of these measures is that they are not
preference-based, though a preference-based measure has been
derived from the EORTC QLQ-C30, the EORTC-8D [13], which
allows utility values to be estimated. This algorithm as well as
mapping functions between the QLQ-C30 and the EQ-5D has been
estimated in a population with MF [14]. Given the lack of overlap
with some MF-related symptoms noted above, neither the
preference-based EORTC-8D nor mapping was considered sufﬁ-
cient for providing utility values for MF populations. The aim of
this study was therefore to derive a preference-based measure for
MF from the MF-SAF and the QLQ-C30 that captures the HRQOL of
patients with MF.Methods
This study involved a ﬁve-step process to derive a health state
classiﬁcation system using an existing data set followed by
valuation of the classiﬁcation system to generate utility values
based on methods originally developed for this purpose by
Brazier et al. [15] and subsequently to generate the EORTC-8D
[13].Data
Data were from the Controlled Myeloﬁbrosis Study with Oral JAK
Inhibitor Treatment (COMFORT-I) trial, a randomized, double-
blind, placebo-controlled phase III study of the oral JAK1/JAK2
inhibitor INCB018424 (ruxolitinib) in patients with primary MF,
post–polycythemia vera MF, or post–essential thrombocythemia
MF conducted in 68 sites in the United States, 6 sites in Canada,
and 15 in Austria [16]. A total of 309 participants were recruited,
and 248 completed the study. Their mean age was 67  8.78 years
(range, 40–91 years), and 54% were men. Respondents completed
a number of questionnaires including both the MF-SAF 2.0 and
the EORTC QLQ-C30.
MF-SAF 2.0 seven-item scores range from 0 (“absent” symp-
toms) to 10 (“worst imaginable” symptoms), and the total symp-
tom score is the sum of the individual scores, excluding inactivity
(see Appendix 1 in Supplemental Materials found at http://dx.doi.
org/10.1016/j.jval.2015.07.004). In COMFORT-I, the MF-SAF 2.0
diary was collected daily over 24 weeks.
The EORTC QLQ-C30 questions [8] from ﬁve of the functioning
scales and nine of the symptom scales were used in the analysis.
The global quality-of-life and ﬁnancial impact items are unsuitable
for inclusion in a health state classiﬁcation system of a preference-
based measure and are excluded from the analyses. The QLQ-C30
was administered at baseline and 24-week follow-up.Analysis
The aim was to produce a classiﬁcation system amenable to
valuation by respondents with a minimum loss of information
while ensuring that the MF-SAF and QLQ-C30 responses could be
unambiguously converted into the classiﬁcation system. The
analysis followed ﬁve steps [15] that have been used to derive
other condition-speciﬁc preference-based measures from both
single measures [17,18] and a battery of measures used in
epilepsy [19]. This study extends the latter approach by deriving
a single condition-speciﬁc preference-based measure from two
measures.
Step 1: Dimensional Structure
The dimensionality of the QLQ-C30 and the MF-SAF 2.0 was
assessed separately for each measure and together for both
measures using factor analysis to determine the dimensions
across both measures and all items. Separate assessment allowed
the identiﬁcation of different factors within each measure,
whereas joint assessment allowed the identiﬁcation of common
factors across the measures. Scree plots were used to conﬁrm the
number of factors with eigenvalues greater than 1 used as a
cutoff for inclusion of factors. Item loading was used to assess
which factor the item was contributing toward, with higher
absolute values indicating greater contribution [20]. Variance of
the item not explained by the common factors and uniqueness
were used to indicate items that may be measuring something
outside the common factors.
Step 2: Item Selection
In the preference-based measure, each dimension needs to be
represented using the minimum number of items from the
original measure and the selected item(s) must best represent
the overall dimension. This selection was undertaken using
classical psychometric analysis and Rasch analysis.
Conventional psychometric tests were used to assess the
practicality and validity of the items. A strong item for selection
should have low levels of missing data, high correlation with the
dimension score, and responses across the severity range and
should be able to discriminate between severity levels and be
responsive to change over two points in time [21,22].
Rasch analysis is a mathematical technique that converts
categorical item responses to a continuous latent scale using a
logit model [23,24]. It was used to assess whether items ﬁtted the
dimension and that they covered the severity of the health
problem as well as the extent to which items had response
choices that were appropriately ordered and whether items
perform the same between populations (testing for differential
item functioning) [21,22]. Items that did not meet these criteria
were candidates for being excluded from the classiﬁcation sys-
tem. An equality test and selection of divergent items using a t
test were undertaken to conﬁrm the dimension structure of the
MF-SAF. Local dependency was examined to determine whether
items were redundant. Rasch analysis was undertaken on the
MF-SAF using the average data for days 1 to 7 (baseline) excluding
the inactivity item. Validation was done using MF-SAF day 1
data. Results from previous Rasch analyses on the properties of
the QLQ-C30 items were used to select items from the QLQ-C30
[13].
Step 3: Validation of the Classiﬁcation System
Face validity of the MF-8D classiﬁcation system was examined
using a small sample of clinicians who had patients with MF.
They were asked their opinions on each of the proposed dimen-
sions including whether the aspect of HRQOL was valid as a
Table 1 – Characteristics of respondents in the
valuation survey.
Characteristic Included
respondents
(n ¼ 244)*
England†
Age (y), mean  SD 38.0  14.8 38.6
Age distribution (y) (%)
18–40 61.1 41.6
41–65 33.6 39.1
>65 5.3 19.3
Sex: female (%) 62.3 51.3
White British (%) 82.0
Employed or self-
employed (%)
69.7 60.9
Unemployed (%) 3.7 3.4
Full-time student (%) 16.8 7.3
Retired (%) 6.1 13.5
Secondary school is
highest level of
education (%)
11.9 NA
Completed university
(%)
59.0
EQ-5D-5L score,
mean  SD
0.92  0.13 0.86  0.23†
EQ-5D-5L, ﬁve-level EuroQol ﬁve-dimensional questionnaire; NA,
not applicable.
* Eight respondents were excluded: four for valuing all states as
identical and less than 1; two for valuing PITS higher than every
other state; and two for valuing all states as worse than
being dead.
† Interviews conducted in the Measurement and Valuation of
Health (MVH) study in 1993 [27].
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 8 4 6 – 8 5 5848separate category, and also asked to consider whether additional
or alternative dimensions would improve the classiﬁcation
system.
Step 4: Valuation
It is infeasible to value all health states deﬁned by the classi-
ﬁcation system because the total number is too large. A sample of
health states was selected for valuation using an orthogonal
array that enables the estimation of an additive regression model
estimating utility values for every health state. An orthogonal
array generated using IBM SPSS statistics version 21 [25] selected
32 health states. These were ﬁrst divided into mild and moderate
states and then randomly allocated in turn into four combina-
tions of eight health states, known as “blocs.” Each respondent
valued health states in one card bloc, plus the worst health state
deﬁned by the classiﬁcation system.
Valuation survey
Selected health states were valued by a general population
sample using time trade-off (TTO). Interviewers were each
provided a sex and age quota of respondents to ensure the
interviewee sample was representative of the UK general pop-
ulation in terms of age and sex. Each interviewer found willing
participants using convenience methods.
At the interview, respondents were provided with a description
of MF (see Appendix 2 in Supplemental Materials found at http://
dx.doi.org/10.1016/j.jval.2015.07.004). Respondents were asked to
read and complete the MF-8D classiﬁcation system for their own
health to familiarize themselves with the classiﬁcation system.
Respondents then valued nine health states (one card bloc plus
the worst health state) plus “full health” and “dead” using the
visual analogue scale, where 100 represents “best possible state of
health” and 0 represents “worst possible state of health.” This was
a warm-up task to encourage respondents to think about the
ordering of the health states and their relative value.
This was followed by a practice TTO question using a moderate
health state and then by a TTO task for the nine health states
presented in a random order. Respondents were ﬁrst asked
whether the health state was better or worse than being dead.
For health states better than dead, the Measurement and Valuation
of Health TTO protocol with a visual prop design was used [2].
Respondents were asked to choose between 1) health state h for 10
years, after which they will die, or 2) full health for z years (zr 10),
after which they will die. The ping-pong titration method was used
to determine the value of z when respondents are indifferent
between 1) and 2), when the number of years in full health changes
from 10 to 0.5, from 9.5 to 1, and so forth. For health states worse
than dead, the lead-time TTO method was used [26]. Respondents
were asked to choose between 1) 10 years in full health plus health
state h for 10 years, after which they will die, or 2) full health for z
years (zr 10), after which they will die. The ping-pongmethod was
used to determine the value of z when respondents are indifferent
between 1) and 2). At the end of the interview, respondents self-
completed the EQ-5D and sociodemographic questions.
Valuation data
There were 252 successfully conducted interviews. A total of 244
respondents are included in the analyses. Eight respondents were
excluded from the analysis; four for valuing all states as identical
and less than one; two for valuing PITS, that is, the worst health
state, higher than every other state; and two for valuing all health
states as worse than being dead because arguably they did not think
life was worth living in any impaired state. Table 1 summarizes the
characteristics of these respondents and compares these character-
istics with characteristics of the general population of England. Thevaluation sample contained a higher proportion of people aged 18 to
40 years, more women, more employed people, more full-time
students, fewer retired people, and fewer people in poor health.
Step 5: Modeling the Utility Values
Utility values were modeled using regression analysis to estimate
values for every health state deﬁned by the classiﬁcation system.
The speciﬁcation is as follows:
yij¼ f ðXδλβÞþεsij ð1Þ
The dependent variable yij is TTO disvalue (generated as 1 − TTO)
for health state i valued by respondent j, and Xδλ is a vector of
dummy explanatory variables for each level λ of dimension δ of
the classiﬁcation system. Level λ ¼ 1 acts as a baseline for each
dimension, and εij is the error term. For dimensions in the
classiﬁcation system derived from the MF-SAF questionnaire,
only one dummy variable is included when the dimension is at
the severity level “worst imaginable.” The error term εij¼ujþeij can
be divided into uj the individual random effect and eij the random
error term for the ith health state valuation of the jth individual.
Models were estimated using ordinary least squares with
robust standard errors, and random effects models with robust
standard errors were also estimated to take into account differ-
ences at the individual level because these models appropriately
deal with the structure of the data when each respondent has
multiple observations [15]. Tobit models that take into account
the bounded nature of the data that is bounded at 1 and –1 were
estimated. Inconsistent coefﬁcients for adjacent severity levels
of a dimension indicate that health deterioration leads to a
higher utility value, contrary to expectations. Models that merge
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tencies were estimated.
Performance of regression models was assessed using the
number of inconsistent coefﬁcients and signiﬁcant coefﬁcients’
mean absolute error (MAE) of predictions at the health state level
and the number of health states in the valuation survey where
MAE is greater than 5% and 10%. MAE was generated using the
difference between observed and predicted utility values at the
health state level, and models with a lower MAE were preferred.
Ethical review for the valuation and content validity studies
was obtained from the Salus Institutional Review Board (Study
no. 0050-0250).Results
Step 1: Dimensional Structure
Factor analysis indicated that the combined QLQ-C30 and MF-SAF
items loaded onto seven factors (see Appendix 3 in Supplemental
Materials found at 10.1016/j.jval.2015.07.004). There was a single
physical, role, and social functioning, fatigue, and dyspnea factor
with the inactivity item from the MF-SAF. The remaining MF-SAF
items loaded onto the second factor with the pain items from the
QLQ-C30. Early satiety was strongly correlated with pain, but
itching and night sweats may have loaded onto this otherwise
pain-related factor because they were highly associated with MF
rather than because they belong to the same factor. Emotional
and cognitive functioning were separate factors, and the remain-
ing three factors had items relating to digestion and sleep
disturbance. Factor analysis of the QLQ-C30 and the MF-SAF
separately conﬁrmed these results (available on request). Further
assessment in steps 2 and 3 was required to conﬁrm the
dimensions.
Step 2: Item Selection
The psychometric analysis indicated that all the MF-SAF items
performed relatively well on the basis of the analysis of missing
data, ﬂoor effects, internal consistency, and responsiveness
although there was some evidence of ceiling effects (Table 2).
For the QLQ-C30, items related to physical functioning (pf1 and
pf2), emotional functioning (ef2 and ef3), all fatigue items,
dyspnea, sleep disturbance, and appetite loss performed well
too. Items with very high ceiling effects such as pf5, nausea,
vomiting, and constipation suggest that these were not common
symptoms for this population. All QLQ-C30 items for role,
cognitive, and social functioning and symptoms related to eating
and digestion (vomiting, pain, constipation, and diarrhea) had
low to very small standardized response means (SRMs) (o|0.20|),
suggesting that these items were not suitable for measuring
change. Items with high levels of ceiling or ﬂoor effects and/or
low responsiveness were excluded from the classiﬁcation system.
The threshold maps from the Rasch analysis show that the six
MF-SAF items were correctly ordered across the 11 severity levels
(Fig. 1). Inactivity was excluded from the Rasch analysis on the
basis that it belonged to a different factor (see step 1). Nineteen
respondents had extreme values (person ﬁt residuals Z|4|), and
these were excluded from further analysis because their scores
can affect the logit scaling. The Rasch analysis on the MF-SAF
indicated that items 3 (abdominal discomfort) and 5 (early
satiety) suffered from local dependency and were tapping into
the same aspect of HRQOL, meaning that one of the items is
redundant and should be excluded (Table 3). Item 6 had uniform
sex differential item functioning; therefore, it was also a candi-
date for exclusion because this item performed differently for
men and women. Rasch models were reestimated excludingitems 3 or 5 and/or item 6, ﬁnding that excluding either item 3
or 5 improved model ﬁt and excluding item 6 along with either
item 3 or 5 also improved model ﬁt.
MF-SAF items 1, 2, 3, and 4 were selected, covering night
sweats, itching, abdominal discomfort, and rib pain. Item 3
(abdominal discomfort) was selected instead of item 5 (early
satiety) because of potential problems with valuation of “feelings
of fullness” (see step 3). The QLQ-C30 items for physical function-
ing (2-pf2 and 3-pf3), fatigue (12-fa3), and dyspnea (8-dy1) were
selected, and the wording from the EORTC-8D was used for
physical functioning and fatigue. Item 22 (ef2 worry) was
included for the emotional functioning dimension because this
had the highest SRM for this dimension. Sleep disturbance and
appetite loss were excluded because the former was associated
with physical functioning and fatigue while the latter was
associated with early satiety.
The proposed classiﬁcation system for validation in step 3 had
eight dimensions: physical functioning, emotional functioning,
fatigue, and dyspnea (from the QLQ-C30) and itching, rib pain on
the left side, abdominal discomfort, and night sweats (from the
MF-SAF). The MF-SAF items had two severity levels, “absent” and
“worst imaginable,” in the classiﬁcation system for valuation
because it is infeasible to value 11 severity levels as members of
the general population are unlikely to be able to distinguish
between these levels.
Step 3: Validation of the Classiﬁcation System
Four MF specialists were asked whether the proposed dimensions
were valid and separate aspects of HRQOL. They were also asked
to consider whether an additional dimension of “bone or muscle
pain” should be included, and whether “feeling of fullness” could
be included as an alternative dimension to “abdominal discom-
fort.” The specialists noted that “shortness of breath” was
important only when doing activities, but the QLQ-C30 question
did not state this. They also felt that there was overlap between
this item and physical functioning; therefore, this was excluded
from the classiﬁcation system. Abdominal discomfort rather than
feeling of fullness was included. All the specialists felt that bone
or muscle pain was an important and distinct symptom of MF
that should be included, and this was therefore added to the
classiﬁcation system. The ﬁnal selected classiﬁcation system had
eight dimensions: physical functioning, emotional functioning,
and fatigue (from the QLQ-C30) and itching, rib pain on the left
side, abdominal discomfort, bone or muscle pain, and night
sweats (from the MF-SAF) (Fig. 2). The classiﬁcation described a
total of 2560 health states.
Step 4: Valuation Survey
Descriptive statistics for observed TTO utility values for all health
states included in the valuation survey (ordered by mean health
state utility value) show that in general the misery score (gen-
erated using the summed severity levels of each health state
using equal severity weighting for each dimension) decreases as
the mean and median utility values decrease (see Appendix 3 in
Supplemental Materials found at 10.1016/j.jval.2015.07.004). The
precise ordering of the misery score and the mean TTO value,
however, differ. This may occur because the misery score
assumes that all dimensions are equally weighted whereas this
may not be true for utility values. In addition, the difference in
mean utility values between many health states is small, at 0.01
or 0.02. Utility values were distributed across the full potential
range from –1 to 1. Most of the values were greater than zero,
meaning that the health state was regarded as being better than
dead, but there was also a peak of values at –1, with few values
lying between –1 and 0.
Table 2 – Psychometric analysis of MF-SAF and QLQ-C30 items (n ¼ 263).
Item no. Item wording % missing
data
% response at
ﬂoor (very
much/worst)
% response at
ceiling (not at
all/absent)
Correlation*,† SRM
MF-SAF
MF-SAF01 Worst night sweats (ﬂushed) 3.6 1.1 16.9 0.724 –0.31
MF-SAF02 Worst itchiness 3.6 0.8 25.6 0.699 –0.33
MF-SAF03 Worst abdominal discomfort 3.6 1.1 5.3 0.901 –0.36
MF-SAF04 Worst pain under ribs on left 3.6 0.8 18.4 0.842 –0.39
MF-SAF05 Worst feeling fullness (early
satiety)
3.6 0.4 7.1 0.872 –0.34
MF-SAF06 Worst bone or muscle pain 3.6 1.1 18.0 0.756 –0.20
MF-SAF07 Worst degree of inactivity 3.6 0.4 7.5 Not in total –0.29
EORTC QLQ-C30 Domain score
Physical functioning
pf1 Trouble with strenuous activities? 4.2 17.7 14.3 –0.833 –0.19
pf2 Trouble with taking a long walk? 3.9 24.1 12.8 –0.893 –0.21
pf3 Trouble taking a short walk? 3.9 2.6 52.6 –0.824 –0.08
pf4 Stay in bed or chair during the
day?
3.9 3.0 45.5 –0.671 –0.15
pf5 Help eating, dressing, washing? 4.5 0.4 94.4 –0.335 0.05
Role functioning
rf1 Limited in work or daily activities? 4.2 8.6 32.3 –0.910 0.07
rf2 Limited in pursuing hobbies? 4.5 11.3 33.8 –0.919 0.00
Emotional functioning
ef1 Did you feel tense? 4.9 3.8 47.4 –0.786 –0.10
ef2 Did you worry? 4.2 4.5 33.8 –0.866 –0.24
ef3 Did you feel irritable? 4.2 3.4 41.0 –0.814 –0.20
ef4 Did you feel depressed? 5.2 3.0 50.8 –0.811 –0.06
Cognitive functioning
cf1 Difﬁculty concentrating on things? 4.2 0.8 59.8 –0.799 –0.05
cf2 Have had difﬁculty remembering
things?
4.9 1.9 49.2 –0.830 –0.02
Social functioning
sf1 Interfered with family life? 4.2 6.0 40.6 –0.910 –0.04
sf2 Interfered with social activities? 4.9 9.0 28.6 –0.928 –0.04
Fatigue
fa1 Did you need to rest? 4.2 13.9 8.3 0.873 –0.23
fa2 Have you felt weak? 4.2 13.9 15.4 0.865 –0.23
fa3 Were you tired? 4.9 21.1 5.3 0.886 –0.26
Nausea and vomiting
ns1 Have you felt nauseated? 4.5 1.1 67.7 0.983 –0.25
vt1 Have you vomited? 4.2 0.0 92.9 0.504 –0.03
Pain
pa1 Have you had pain? 4.5 5.3 31.6 0.931 0.00
pa2 Pain interferes with daily
activities?
4.5 4.1 49.6 0.917 –0.02
dy1 Were you short of breath? 4.5 9.0 26.7 – –0.20
sl1 Have you had trouble sleeping? 4.9 10.5 26.3 – –0.25
al1 Have you lacked appetite? 4.2 7.5 36.8 – –0.33
co1 Have you been constipated? 3.9 2.6 67.3 – –0.07
di1 Have you had diarrhea? 4.5 2.3 56.8 – –0.03
MF-SAF, Myeloﬁbrosis-Symptom Assessment Form; QLQ-C30, Cancer Quality of Life 30 Questionnaire; SRM, standardized response mean.
* Values for correlation for the MF-SAF are for MF-SAF total.
† Values for correlation for the EORTC QLQ-C30 are for domain score.
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The ordinary least squares, random effects maximum likelihood
estimator (RE MLE), and Tobit models had inconsistent but non-
signiﬁcant coefﬁcients for physical functioning level 2 and fatigue
level 2 (Table 4). In addition, the ordinary least squares model had
an inconsistent coefﬁcient for fatigue level 3 and the RE MLEmodel had an inconsistent coefﬁcient for physical functioning
level 4. This means that contrary to expectations as health
worsens utility increases.
Overall, the RE MLE performs best taking into account the
number of signiﬁcant level coefﬁcients, inconsistencies, and the
MAE. Model 4 is a consistent version of the RE MLE model (2), in
which levels of inconsistent coefﬁcients were merged with the
1 Night sweats 2 Itching 3 Abdominal discomfort
4 Rib pain 5 Early satiety 6 Bone/muscle pain
Fig. 1 – MF-SAF item probability curves and threshold map using average data. MF-SAF, Myeloﬁbrosis-Symptom
Assessment Form. (Color version of ﬁgure is available online.)
Table 3 – Myeloﬁbrosis-Symptom Assessment Form (MF-SAF) Rasch results (n ¼ 302).
Item no. Item wording Item-level
ordering
Local
dependency
DIF
(age)
DIF
(sex)
DIF (MF
type)
Fit
residual
Item-
level χ2
Consider
for
exclusion
MF-SAF01 Night sweats
(ﬂushed)
Ordered 2.176 0.458 No
MF-SAF02 Itchiness Ordered 3.352 0.005 No
MF-SAF03 Abdominal
discomfort
Ordered √(MFSAF05) –3.425 0.003 Yes or
MFSAF05
MF-SAF04 Pain under ribs
on left
Ordered –1.82 0.222 No
MF-SAF05 Feeling fullness
(early satiety)
Ordered √(MFSAF03) –2.411 0.041 Yes or
MFSAF03
MF-SAF06 Bone or muscle
pain
Ordered √ 1.515 0.650 Yes
Criteria at the model level
χ2 interaction o0.001
Item ﬁt 0 (0.18)
Person ﬁt –0.79 (0.79)
Person separation index 0.83
Unidimensional (equality test
—proportion with signiﬁcant
differences) (%)
7.8
Note. DIF was tested for age, sex, and the type of MF reported. DIF was assessed on the basis of a Bonferroni-adjusted P value ¼ 0.002778. Item-
level ﬁt assessed on the basis of a Bonferroni-adjusted P value ¼ 0.0017.
√ , presence of local dependency or DIF; DIF, differential item functioning; MF, myeloﬁbrosis.
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MF-SAF health state classification system
During the past week:
Physical functioning
You had no trouble taking a long walk
You had a little trouble taking a long walk
You had quite a bit of trouble taking a long walk
You had very much trouble taking a long walk 
You had very much trouble taking a short walk outside of the house 
Emotional functioning
You did not worry
You worried a little
You worried quite a bit
You worried very much
Fatigue
You were not tired
You were a little tired
You were tired quite a bit
You were tired very much
Itchiness
You had no itchiness
Your worst itchiness was the worst imaginable
Pain under ribs on the left side
You had no pain under your ribs on the left side
Your worst pain under your ribs on the left side was the worst imaginable
Abdominal discomfort (feel uncomfortable, pressure or bloating)
You had no abdominal discomfort
Your worst abdominal discomfort was the worst imaginable
Bone or muscle pain
You had no bone or muscle pain
Your worst bone or muscle pain was the worst imaginable
Night sweats (or feeling hot and flushed)
You had no night sweats
Your worst night sweats were the worst imaginable
Fig. 2 – MF-SAF health state classiﬁcation system. MF-SAF,
Myeloﬁbrosis-Symptom Assessment Form.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 8 4 6 – 8 5 5852adjacent severity level to ensure that as health worsens the
utility value decreases.
These regression models enable a utility value to be deter-
mined for every health state deﬁned by the MF-8D classiﬁcation
system. For dimensions derived from the MF-SAF, however, there
were only two severity levels in the classiﬁcation system, absent
and worst imaginable, whereas respondents were to respond on a
0 to 10 scale, where 0 ¼ absent and 10 ¼worst imaginable. Table 5
reports the utility decrement for these items assuming equal
intervals for each decrement on the 0 to 10 scale (method 1), and
an alternative method using the relative difference in the logit
value generated using the Rasch logit model for each decrement
on the 0 to 10 scale for each individual dimension (method 2).
The MF-8D algorithm was applied to COMFORT-I data, which
contained both the MF-SAF and the EORTC QLQ-C30. The MF-8D
has utility scores ranging from 0.089 to 1. Mean observed utility
scores in the data set were 0.732  0.164 (range 0.226–1) at
baseline and 0.785  0.174 (range 0.110–1) using method 1. Mean
was 0.669  0.161 (range 0.230–1) at baseline and 0.726  0.178
(range 0.104–1) at follow-up using method 2. The difference in
utility scores for the two versions was statistically signiﬁcant at
baseline (mean difference 0.0630  0.040; t232 ¼ 24.3; P o 0.0001)
and follow-up (mean difference 0.0589  0.046; t209 ¼ 18.4; P o
0.0001). As expected, both versions were able to discriminate
between MF-SAF total symptom score groups (baseline MF-8D vs.
method 1 F231,3 ¼ 271, P o 0.001; MF-8D vs. method 2 F231,3 ¼ 203;
P o 0.001) and Eastern Cooperative Oncology Group [28] groups
(baseline MF-8D vs. method 1 F224,2 ¼ 7.6, P o 0.001; MF-8D vs.
method 2 F224,2 ¼ 5.9, P ¼ 0.003). SRMs are 0.36 and 0.39 for utilityscores generated using method 1 and method 2, respectively,
which mirrors SRMs from the MF-SAF 2.0 items.Discussion
This study derived the classiﬁcation system and corresponding
utility values for MF-8D, a condition-speciﬁc preference-based
measure for MF derived from the MF-SAF and the generic cancer
measure EORTC QLQ-C30. The generated MF-8D utility values can
be used to estimate quality-adjusted life-years for use in eco-
nomic evaluation using data from past and future myeloprolifer-
ative neoplasm conditions trials that have used both measures.
The classiﬁcation system has eight dimensions: physical func-
tioning, emotional functioning, fatigue, night sweats, itchiness,
abdominal discomfort, pain under the left rib, and bone or
muscle pain, with four or ﬁve severity levels for the ﬁrst three
dimensions and two levels for the last ﬁve dimensions. The
inclusion of MF-speciﬁc symptoms and the exclusion of symp-
toms such as nausea and vomiting that were not relevant in this
population means that this measure is better suited for generat-
ing utility values than either the EORTC-8D or mapped values to
the EQ-5D.
The RE MLE model was the best performing model, and the RE
MLE model with consistent coefﬁcients is recommended for use
in generating utility values. Two methods were used to derive
utility values for patient responses for the MF-8D dimensions
derived from the MF-SAF: method 1 assumed equal intervals
across the 0 to 10 scale, and method 2 used results from the
Rasch logit model. Utility scores derived using both methods
were able to discriminate across groups with known differences
as well as capture change over time in a similar manner to the
original measures. Method 2 has the advantage that it divides the
utility weight in a way that is consistent with the impact of each
decrement on the underlying health of the patient. There is no
reason, however, to expect that this would equal the preferences
of the general population regarding each decrement on the 0 to
10 scale, and therefore method 1 is the recommended method for
generating utility values.
There are a number of limitations in this study. The MF-8D
was derived from two measures, meaning that the MF-8D can be
applied only when both measures have been used. A potential
solution would be to provide a mapping algorithm between the
MF-SAF 2.0 questions and the MF-8D that would allow utility
values to be generated when only the MF-SAF 2.0 has been used
(available on request).
The use of two measures to derive a single preference-based
measure was a novel approach that has been applied once before
where a battery of measures was used [19]. The rationale was to
take advantage of important core cancer dimensions from the
QLQ-C30 while ensuring that MF-speciﬁc dimensions were cov-
ered. This was supported by the psychometric analysis, which
conﬁrmed that many of the QLQ-C30 items were not relevant or
as responsive in this population as the MF-SAF items. Factor
analysis was undertaken separately for each measure before
combining the measures to ensure that factors were not con-
taminated by instrument-speciﬁc effects. Rasch analysis was
used in the MF-SAF to test the individual items for the single
factor in this measure and to inform item selection [15].
Development of the classiﬁcation system was undertaken
using a single data set that did not cover the full severity range,
but it has not been validated in an external data set because of
lack of data. Clinicians provided input, however, on the face
validity of the items, indicating that they were appropriate for the
condition. There are also common dimensions of physical func-
tioning, emotional functioning, and fatigue in both the MF-8D
and the EORTC-8D, the preference-based measure derived from
Table 4 – Estimated preference weights for the MF-8D
MF-8D variable
levels
1: Ordinary least
squares
2: RE MLE 3: Tobit MF-8D variables
-collapsed levels
4: RE MLE
consistent
model
MF-8D Physical
Functioning 2
–0.017 (0.416) –0.014 (0.234) –0.007 (0.564) MF-8D Physical
Functioning 2
0
MF-8D Physical
Functioning 3
0.070* (0.003) 0.068* (0.000) 0.057* (0.000) MF-8D Physical
Functioning 3 and 4
0.074* (0.000)
MF-8D Physical
Functioning 4
0.091* (0.002) 0.065* (0.000) 0.062* (0.001)
MF-8D Physical
Functioning 5
0.120* (0.000) 0.115* (0.000) 0.103* (0.000) MF8D Physical
Functioning 5
0.122* (0.000)
MF-8D Emotional
Functioning 2
0.017 (0.440) 0.031† (0.023) 0.021‡ (0.085) MF-8D Emotional
Functioning 2
0.031† (0.021)
MF-8D Emotional
Functioning 3
0.041‡ (0.054) 0.049* (0.002) 0.043* (0.000) MF-8D Emotional
Functioning 3
0.048* (0.002)
MF-8D Emotional
Functioning 4
0.068* (0.002) 0.074* (0.000) 0.058* (0.000) MF-8D Emotional
Functioning 4
0.075* (0.000)
MF-8D Fatigue 2 –0.013 (0.560) –0.012 (0.455) –0.010 (0.402) MF-8D Fatigue 2
MF-8D Fatigue 3 –0.004 (0.844) 0.006 (0.704) 0.008 (0.541) MF-8D Fatigue 3 0.013 (0.364)
MF-8D Fatigue 4 0.053† (0.016) 0.066* (0.000) 0.051* (0.000) MF-8D Fatigue 4 0.072* (0.000)
MF-8D Itchiness 2 0.097* (0.000) 0.093* (0.000) 0.084* (0.000) MF-8D Itchiness 2 0.093* (0.000)
MF-8D Pain under Left
Ribs 2
0.145* (0.000) 0.139* (0.000) 0.123* (0.000) MF-8D Pain under Left
Ribs 2
0.139* (0.000)
MF-8D Abdominal
Discomfort 2
0.142* (0.000) 0.145* (0.000) 0.127* (0.000) MF-8D Abdominal
Discomfort 2
0.145* (0.000)
MF-8D Bone/Muscle
Pain 2
0.179* (0.000) 0.178* (0.000) 0.151* (0.000) MF-8D Bone/Muscle
Pain 2
0.178* (0.000)
MF-8D Night Sweats 2 0.073* (0.000) 0.080* (0.000) 0.065* (0.000) MF-8D Night Sweats 2 0.080* (0.000)
Constant 0.029 (0.229) 0.020 (0.342) 0.050† (0.014) Constant 0.007 (0.715)
Observations 2196 2196 2196 2196
R2 0.251
Number of ID 244 244 244
Inconsistencies 3 3 2 0
Signiﬁcant-level
coefﬁcients
11 12 12 11
MAE 0.018 0.021 0.049 0.022
MAE 4 0.05 3 3 8 3
MAE 4 0.10 0 0 4 0
Note. P values in parentheses. MAE, mean absolute error; MF-8D, Myeloﬁbrosis 8 dimensions; RE MLE, random effects maximum likelihood
estimator.
* Signiﬁcant at 1%.
† Signiﬁcant at 5%.
‡ Signiﬁcant at 10%.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 8 4 6 – 8 5 5 853the QLQ-C30, which provides some external validity [13]. Inter-
estingly, the remaining ﬁve dimensions in each measure differ,
suggesting that the dimensions of the HRQOL differ across
different cancer populations, and this raises questions regarding
the appropriateness and usage of a single preference-based
measure for cancer. The approach taken by cancer measure
developers such as the EORTC group [9] and the Functional
Assessment of Chronic Illness Therapy group [29] is to provide
cancer-speciﬁc modules alongside the core measures, which
suggests that a single measure is not sufﬁcient, but a module
has not been provided in MF.
The valuation sample was younger and healthier and had a
higher level of education than did the general population,
indicating that it was not representative. This group may havepreferences different from those in the general population. The
preferred model, however, ﬁts the data well, with low error in
predicting health state utility values at the health state level.
The valuation survey design used an orthogonal array to select
health states that assumes independence between all dimensions.
Although responses to the MF-SAF dimensions were correlated, the
assumption of independence was deemed appropriate due to the
apparent difference in the underlying symptoms of the dimen-
sions. Respondents in the valuation survey did not indicate that
this affected the plausibility of the health states they valued.
A ﬁnal limitation is that the MF-SAF dimensions have two
severity levels for dimensions from the MF-SAF, whereas patients
self-report their health using a 0 to 10 scale. This means that
preferences have been elicited only for the extreme ends of this
Table 5 – Preference weights for MF-SAF dimensions of the MF-8D by response
Dimension Response on the 0–10 scale
0 1 2 3 4 5 6 7 8 9 10
Method 1: Using equal interval
Night sweats (or feeling
hot and ﬂushed)
0 0.0080 0.0160 0.0240 0.0320 0.040 0.0480 0.0560 0.0640 0.0720 0.0800
Itchiness 0 0.0093 0.0186 0.0279 0.0372 0.0465 0.0558 0.0651 0.0744 0.0837 0.0930
Abdominal discomfort
(feel uncomfortable,
pressure, or bloating)
0 0.0145 0.0290 0.0435 0.0580 0.0725 0.0870 0.1015 0.1160 0.1305 0.1450
Pain under ribs on the
left side
0 0.0139 0.0278 0.0417 0.0556 0.0695 0.0834 0.0973 0.1112 0.1251 0.1390
Bone or muscle pain 0 0.0178 0.0356 0.0534 0.0712 0.0890 0.1068 0.1246 0.1424 0.1602 0.1780
Method 2: Using Rasch item logit thresholds
Night sweats (or feeling
hot and ﬂushed)
0 0.0250 0.0338 0.0410 0.0471 0.0524 0.0573 0.0621 0.0672 0.0731 0.080
Itchiness 0 0.0384 0.0415 0.0441 0.0467 0.0499 0.0541 0.0600 0.0681 0.0789 0.093
Abdominal discomfort
(feel uncomfortable,
pressure, or bloating)
0 0.0446 0.0608 0.0726 0.0815 0.0888 0.0957 0.1034 0.1134 0.1268 0.145
Pain under ribs on the
left side
0 0.0582 0.0645 0.0688 0.0721 0.0758 0.0809 0.0886 0.1001 0.1165 0.139
Bone or muscle pain 0 0.0659 0.0741 0.0819 0.0901 0.0990 0.1095 0.1220 0.1372 0.1556 0.178
MF-SAF, Myeloﬁbrosis-Symptom Assessment Form; MF-8D, Myeloﬁbrosis 8 dimensions.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 8 4 6 – 8 5 5854scale and have been divided equally as well as on the basis of the
Rasch logit scale to produce a utility decrement for every point on
the 0 to 10 scale, and this may not reﬂect the preferences of the
sample in the valuation survey.
Despite these limitations, results from this study provide a
condition-speciﬁc preference-based measure that can be used to
generate utility values in a population with MF in which the MF-
SAF 2.0 (or other versions with similar questions) and the QLQ-
C30 have been used. Future research assessing the validity of the
classiﬁcation system of the MF-8D in an external data set
including comparisons with generic preference-based measures
such as the EQ-5D is recommended.Acknowledgments
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